Is tildrakizumab , a novel anti-IL-23 monoclonal antibody , unaffected by ethnic variability in Caucasian , Chinese , and Japanese subjects?
The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects. Tildrakizumab exposure increased proportionally with dose in the range of 50-400 mg. A single SC dose of 50, 200, and 400 mg or a single IV dose of 10 mg/kg was generally well tolerated.
Minority women are among the least active subgroups in American society, although not all groups are less active than White women when all domains of physical activity are taken into account.